Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2012-05-24

Clinical Trial Update: Safety and Efficacy Study of Icotinb in Non-small Cell Lung Cancer (NSCLC) Patients [Phase 3]

View source ↗

Summary

Phase 3 study of icotinib in non-small cell lung cancer completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • icotinib (icotinib)

Snippet

Sponsor: Betta Pharmaceuticals Co., Ltd. | Conditions: Non-small Cell Lung Cancer | Phase 3 | Status: COMPLETED | Results posted: 2012-05-24